Till Jacob E, Seewald Nicholas J, Yazdani Zachariya, Wang Zhuoyang, Ballinger Dominique, Samberg Heather, Dandu Siri, Macia Camilla, Yin Melinda, Abdalla Aseel, Prior Timothy, Shah Shivani S, Patel Thara, McCoy Emily, Mansour Maikel, Wills Carson A, Bochenek Veronica, Serrano Jonathan, Snuderl Matija, Phillips Richard E, O'Rourke Donald M, Amankulor Nduka M, Nabavizadeh Ali, Desai Arati S, Gollomp Kandace, Binder Zev A, Zhou Wanding, Bagley Stephen J, Carpenter Erica L
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania.
Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Clin Cancer Res. 2025 Apr 1;31(7):1292-1304. doi: 10.1158/1078-0432.CCR-24-3169.
Noninvasive prognostic biomarkers to inform clinical decision-making are an urgent unmet need for the management of patients with glioblastoma (GBM). We previously showed that higher circulating cell-free DNA (ccfDNA) concentration is associated with worse survival in GBM. However, the biology underlying this is unknown.
We prospectively enrolled 129 patients with treatment-naïve GBM with blood drawn prior to initial resection (baseline) and at the time of the first postradiotherapy MRI. We performed ccfDNA methylation deconvolution to determine cellular sources of ccfDNA. ELISA was performed to detect citrullinated histone 3 (citH3), a marker of neutrophil extracellular traps (NET). Multiplex proteomic analysis was used to measure soluble inflammatory proteins.
We found that neutrophils contributed the highest proportion of prognostic ccfDNA. The percentage of ccfDNA derived from neutrophils was correlated with total [ccfDNA] but only in patients receiving preoperative corticosteroids. At baseline and on therapy, [citH3] was significantly higher in the plasma of patients with GBM receiving corticosteroids compared with corticosteroid-naïve GBM or no-cancer controls. Unsupervised hierarchical clustering of ccfDNA methylation patterns yielded two clusters, with one enriched for patients with the NETosis phenotype and who received corticosteroids. Unsupervised clustering of circulating inflammatory proteins yielded similar results.
These data suggest neutrophil-mediated NETosis is the dominant source of prognostic ccfDNA in patients with GBM and may be associated with glucocorticoid exposure. If further studies show that pharmacological inhibition of NETosis can mitigate the deleterious effects of corticosteroids, these plasma markers will have important clinical utility as noninvasive correlative biomarkers.
用于指导临床决策的非侵入性预后生物标志物是胶质母细胞瘤(GBM)患者管理中亟待满足的需求。我们之前表明,循环游离DNA(ccfDNA)浓度升高与GBM患者较差的生存率相关。然而,其背后的生物学机制尚不清楚。
我们前瞻性招募了129例未经治疗的GBM患者,在初次切除术前(基线)和首次放疗后MRI检查时采集血液。我们进行了ccfDNA甲基化反卷积以确定ccfDNA的细胞来源。采用酶联免疫吸附测定(ELISA)检测中性粒细胞胞外诱捕网(NET)的标志物瓜氨酸化组蛋白3(citH3)。使用多重蛋白质组分析来测量可溶性炎症蛋白。
我们发现中性粒细胞对预后ccfDNA的贡献比例最高。源自中性粒细胞的ccfDNA百分比与总[ccfDNA]相关,但仅在接受术前皮质类固醇治疗的患者中如此。在基线和治疗期间,接受皮质类固醇治疗的GBM患者血浆中的[citH3]明显高于未接受皮质类固醇治疗的GBM患者或无癌症对照组。ccfDNA甲基化模式的无监督层次聚类产生了两个聚类,其中一个聚类富含具有NETosis表型且接受皮质类固醇治疗的患者。循环炎症蛋白的无监督聚类产生了类似的结果。
这些数据表明,中性粒细胞介导的NETosis是GBM患者预后ccfDNA的主要来源,并且可能与糖皮质激素暴露有关。如果进一步的研究表明对NETosis的药物抑制可以减轻皮质类固醇的有害影响,那么这些血浆标志物将作为非侵入性相关生物标志物具有重要的临床应用价值。